We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 127

Brexit: Life Sciences implications
  • Bird & Bird
  • European Union, United Kingdom
  • January 24 2017

On 23 June 2016, the UK public voted to leave the EU. The Prime Minister subsequently announced an intention to serve notice of withdrawal under


Does requesting and receiving approval for a pharmaceutical create a threat of patent infringement? A German perspective
  • Bird & Bird
  • Germany
  • February 28 2008

Under German law, neither the application for a marketing approval nor obtaining it constitutes a ‘use’ act under Section 9 German Patent Act


Edwards Lifesciences AG v Cook Biotech Incorporated
  • Bird & Bird
  • United Kingdom
  • July 17 2009

Mr Justice Kitchin handed down a decision only four weeks after the hearing, finding Cook’s patent invalid and not infringed by Edwards’ SAPIEN heart valve


Patent decisions on patents for chiral compounds
  • Bird & Bird
  • United Kingdom
  • May 13 2009

A chiral compound is one which has at least one asymmetric carbon centre


Confidentiality in clinical trials
  • Bird & Bird
  • Netherlands
  • October 16 2008

Confidentiality covering clinical trials is important in the context of obtaining patent protection for an invention that is the subject of a clinical trial


Court of Appeal reverses earlier decision on the definition of “offering” a patented product
  • Bird & Bird
  • Sweden
  • December 20 2007

As reported in Life Sciences Update in December 2006, the District Court found that an application for registration with the Pharmaceutical Benefits Register and request for pricing was considered as an “offering” of the product, and thus constituted patent infringement


Patenting stem cells
  • Bird & Bird
  • Singapore
  • March 11 2009

The life sciences initiative in Singapore began in 2000 when it was identified as the fourth pillar of Singapore’s economy


End of German Olanzapine battle: Federal Supreme Court upholds patent
  • Bird & Bird
  • Germany
  • March 11 2009

On December 16, 2008 the Federal Supreme Court gave its judgment determining the validity of the Olanzapine patent, this was further to its revocation by the Federal Patent Court at first instance


Status of the insufficiencyobviousness squeeze - an appraisal of the House of Lords’ Generics et al v Lundbeck judgments
  • Bird & Bird
  • United Kingdom
  • May 1 2009

In February 2009 the House of Lords unanimously dismissed an appeal by a number of pharmaceutical companies against the Court of Appeal’s decision to not revoke Lundbeck’s escitalopram patent on grounds of insufficiency


Pfizer’s arrangements with Unichem
  • Bird & Bird
  • United Kingdom
  • October 30 2007

The High Court dismissed an application for an interim injunction by AAH Pharmaceuticals Limited and seven other pharmaceutical wholesalers to restrain the implementation of Pfizer Limited’s new single “direct to pharmacy” distribution arrangements for its prescription drugs in the UK